GT Biopharma Inc/$GTBP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About GT Biopharma Inc
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
- Ticker
- $GTBP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1
- Headquarters
- San Francisco, United States
- Website
- www.gtbiopharma.com
GT Biopharma Inc Metrics
BasicAdvanced
$7.1M
-
-$13.22
0.91
-
Price and volume
Market cap
$7.1M
Beta
0.91
52-week high
$11.98
52-week low
$3.88
Average daily volume
62K
Financial strength
Current ratio
2.608
Quick ratio
2.235
Interest coverage (TTM)
-64.32%
Profitability
Management effectiveness
Return on assets (TTM)
-158.16%
Return on equity (TTM)
-113.52%
Valuation
Price to book
1.98
Price to tangible book (TTM)
1.98
Price to free cash flow (TTM)
-0.233
Free cash flow yield (TTM)
-429.90%
Free cash flow per share (TTM)
-17.024
Growth
Earnings per share change (TTM)
-96.67%
3-year earnings per share growth (CAGR)
-65.10%
GT Biopharma Inc Financial Performance
Revenues and expenses
GT Biopharma Inc Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.